Wells Fargo Upgrades Infinity Pharmaceutical (INFI) to Overweight, Sees Upside to $30

July 28, 2021 4:36 AM EDT
Get Alerts INFI Hot Sheet
Price: $3.63 +6.14%

Rating Summary:
    13 Buy, 7 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 7 | Down: 15 | New: 24
Trade Now! 
Join SI Premium – FREE

(Updated - July 28, 2021 9:28 AM EDT)

Wells Fargo analyst Nick Abbott upgraded Infinity Pharmaceutical (NASDAQ: INFI) from Equal Weight to Overweight with a price target of $14.00.

The analyst commented, "Following updated clinical data for eganelisib in urothelial bladder cancer (UBC) showing an impressive 40% reduction in risk of death compared to control and highly encouraging clinical/biomarker data in triple negative breast cancer (TNBC) we are increasing our price target on shares of Infinity Pharmaceuticals (INFI) from $4 to $14/share and changing our rating to Overweight from Equal Weight with upside potential to $30 given a doubling of probability of success. We view the decline in stock price as a good buying opportunity ahead of a more mature TNBC update and finalization of registration plans in UBC by YE21. In addition, following filing of the company's 10Q our 2021/22 EPS is -$0.55 vs -$0.57/ -$0.58 vs -$0.61 prior INFI ended the quarter with a cash balance of $97.3MM and an ATM balance of $87.1MM."

For an analyst ratings summary and ratings history on Infinity Pharmaceutical click here. For more ratings news on Infinity Pharmaceutical click here.

Shares of Infinity Pharmaceutical closed at $1.52 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, Hot Comments, Hot Upgrades, Upgrades

Related Entities

Wells Fargo